Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:4/1/2009

lacement closes. The foregoing disclosure regarding the "going concern" opinion is required under NASDAQ rules and requires that a company receiving an audit opinion that expresses doubt about the ability of the company to continue as a going concern make a public announcement disclosing the receipt of such opinion. With the anticipated proceeds from the initial closing of the private placement announced today, Sunesis believes that it has sufficient resources to fund its operations at least through the end of 2009.

Financial Highlights

  • No material revenue was recorded in the fourth quarter of 2008, compared to $1.8 million in the fourth quarter of the prior year. Revenue totaled $5.4 million for the year ended December 31, 2008, compared to $9.7 million for the year ended December 31, 2007. The decrease in revenue year-over-year was primarily due to the conclusion of the research phase of the kinase inhibitor collaboration with Biogen Idec in June 2008 and lower amortization of license fees and milestone payments from our collaboration with Merck & Co., Inc.
  • Research and development (R&D) expense was $4.6 million for the fourth quarter of 2008, compared to $8.3 million for the same period in 2007. R&D expense for the year ended December 31, 2008 totaled $26.3 million, compared to $36.1 million in 2007. The quarter-over-quarter and year-over-year decrease in R&D expense was primarily due to the termination of discovery research activities in June 2008 and decrease in clinical trial activities related to SNS-032 and SNS-314, partially offset by increased clinical trial activities related to voreloxin.
  • General and administrative (G&A) expense for the fourth quarter of 2008 was $2.2 million, compared to $2.8 million for the fourth quarter of 2007. For the year ended December 31, 2008, G&A expense was $11.5 millio
    '/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Mich. , June 1, 2015  Neogen Corporation (NASDAQ: ... assets of Sterling Test House, a leading commercial food testing ... that the acquired laboratory will serve as a base for ... Sterling Test House was incorporated ... all of the food safety and water quality testing for ...
(Date:6/1/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX: RVX) (the "Company") ... at the ERA-EDTA Congress in London, England ... a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in ... Disease (CKD); a Post-hoc Analysis of Patients from the ... Dr. Kam Kalantar-Zadeh , Professor and Chief, Division ...
(Date:6/1/2015)... 1, 2015  Berg, a biopharmaceutical company committed to ... clinical research from its trials using its cancer drug ... data on triple negative breast cancer, at the 51 ... Clinical Oncology (ASCO), May 29 – June 2 in ... 31510 is one of the first cancer drugs guided ...
(Date:6/1/2015)... , June 1, 2015 ... that it will be participating in the Jefferies 2015 ... on Tuesday, June 2, 2015. Jeff ... question and answer session at 10:00 a.m. ET (3:00 ... be available on the Presentations and Webcasts section of ...
Breaking Biology Technology:Neogen acquires India food safety company 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3
... DUBLIN, Ireland, April 20 Shire plc (LSE: SHP,NASDAQ: SHPGY ), ... 30, 2009. , , Results press release will be issued ... Investor conference call time: ... / 09:30 EDT, , Live conference call for investors: ...
... FREMONT, Calif., April 20 Quark Pharmaceuticals, Inc., ... RNA interference (RNAi)-based therapeutics, today announced that James ... give a presentation on Tuesday, April 20 at ... Therapeutics (ASPET) Annual Meeting, which is taking place ...
... EMERYVILLE, Calif., April 20 Bionovo, Inc. (Nasdaq: ... data on the nature of the active compound and mechanism ... presentation is being made at the 2009 conference of the ... the study concludes the following:, , ...
Cached Biology Technology:Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009 2Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting 2Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting 3Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 2Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 3
(Date:5/29/2015)... May 28, 2015 Research and Markets ... the "Facial Recognition Market by Solution, by ... Forecast to 2020" report to their offering. ... facial recognition technology become more efficient and cost ... traction and investment from the commercial sector. The ...
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
(Date:5/25/2015)... May 25, 2015  Australia,s market for wearable technologies ... 2014 saw the advent of several trials and prototypes. ... 2015 is expected to ignite interest in wearables as ... Australia . This in turn will spur ... drive new partnerships amongst vendors and distributors. ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4
... in <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2010-06/aaft-tpr060910.php,">Chinese . MADISON, ... livestock manure is a common source of agricultural ... of scientists has developed an application of rare ... from soils receiving livestock manure. In addition to ...
... a small group of microbiologists is revealing how marine microbes ... just beneath the deep ocean floor. The ocean crust may ... Orcutt, a post-doctoral fellow at Aarhus University in Denmark and ... this little researched realm today at Goldschmidt 2010, an annual ...
... June 9 Black Diamond Advanced Technology has designed ... secure and efficient multi-modal biometrics collection in the field. Called ... new embedded-processor dual-iris camera system, which is capable of outdoor, ... a rugged platform.   , ...
Cached Biology News:Tracking phosphorus runoff from livestock manure 2New research into the deep ocean floor yields promising results for microbiologists 2Black Diamond Achieves Rapid Dual-Iris Capture With New Rugged Handheld Biometrics Device 2Black Diamond Achieves Rapid Dual-Iris Capture With New Rugged Handheld Biometrics Device 3
... carriers to suit the widest possible range ... science laboratory. Labware carriers can be placed ... is simple for the user, thanks to ... are correctly guided into position. This allows ...
... standard is a new tuning and calibration ... mass spectrometry. Accumix is a lyophilized ... coverage for both tuning and calibration of ... and Fourier transform mass spectrometers. Direct ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Biology Products: